| Scorecard |
|---|
|
4 / 5 Stars
|
|
Lipper
3
3
5
1
1
|
|
Zacks Investment Research
2
(Buy)
|
|
Standard & Poor's
3 / 5 Stars
|
|
TheStreet.com
A+
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Short | % Net | |
|---|---|---|---|
| Cash | 2.73 | 0.84 | 1.89 |
| Stocks | 77.24 | 0.0 | 77.24 |
| Bonds | 0.0 | 0.0 | 0.0 |
| Other | 0.13 | 0.01 | 0.12 |
| Foreign Bonds | 0.0 | 0.0 | 0.0 |
| Foreign Stocks | 20.76 | 0.0 | 20.76 |
| Convertible | 0.0 | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 | 0.0 |
Updated 04.30.2013
Top 10 Holdings
Performance as of 05.31.2013
Portfolio as of 04.30.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Pfizer Inc | PFE | 12.56 | 5.02 |
| Roche Holding AG | RHHVF | 21.67 | 4.61 |
| Gilead Sciences Inc | GILD | 44.64 | 4.5 |
| Celgene Corporation | CELG | 54.06 | 3.86 |
| Novartis AG | NVSEF | 14.18 | 3.81 |
| Amgen Inc | AMGN | 16.09 | 3.81 |
| Johnson & Johnson | JNJ | 22.65 | 3.59 |
| Bristol-Myers Squibb Company | BMY | 48.17 | 3.33 |
| Eli Lilly and Company | LLY | 9.73 | 3.18 |
| Sanofi | SAN | --- | 3.14 |
